Current controversies in data monitoring for clinical trials
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
This article presents some real-life challenges faced by clinical trial Data Monitoring Committees (DMCs), with the aim of clarifying some of the controversial issues that relate to both statistical stopping boundaries and DMC decision-making. Specific attention is given to what constitutes a sensible statistical boundary for stopping a trial early for benefit, bearing in mind that one usually needs proof beyond reasonable doubt of a treatment benefit sufficient to alter future clinical practice. Appropriate choices of stopping boundary for harm and futility are also discussed. The examples serve to illustrate that the practicalities of DMC decision-making require wise judgements based on a totality of evidence, making any statistical boundary just an objective guideline rather than a definitive stopping rule.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“The use of -spending functions [11] allows the timing of interim analyses to be more flexible, and the advent of statistical packages such as EAST and PEST makes such increased complexity more technically manageable.”
MethodDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Contradicted and Initially Stronger Effects in Highly Cited Clinical Research
Ioannidis, J. P. A. (2005) · JAMA · doi:10.1001/jama.294.2.218 · Cited by 1,465
NXY-059 for Acute Ischemic Stroke
Lees, K. R., Zivin, J. A., Ashwood, T., Davalos, A., Davis, S. M., Diener, H.-C., Grotta, J., Lyden, P., Shuaib, A., Hårdemark, H.-G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052980 · Cited by 660
Multiplicity in randomised trials II: subgroup and interim analyses
Schulz, K. F., & Grimes, D. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66516-6 · Cited by 357
A proposed charter for clinical trial data monitoring committees: helping them to do their job well
(2005) · The Lancet · doi:10.1016/s0140-6736(05)17965-3 · Cited by 324 · cited 2×
“Choice of statistical stopping boundaries for benefit A part of good data monitoring practice is to have pre-defined statistical stopping boundaries documented in the DMC Charter [3].”
Background
Cited by
Active learning increases student performance in science, engineering, and mathematics
Freeman, S., Eddy, S. L., McDonough, M., Smith, M. K., Okoroafor, N., Jordt, H., & Wenderoth, M. P. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319030111 · Cited by 9,787
“In addition, best-practice directives suggest that data management committees may allow such studies to stop for benefit if interim analyses have large sample sizes and P values under 0.001 (16).”
BackgroundInfluentialMarine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811403 · Cited by 979
Brok, J., Thorlund, K., Wetterslev, J., & Gluud, C. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyn188 · Cited by 917
Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?
Thorlund, K., Devereaux, P. J., Wetterslev, J., Guyatt, G., Ioannidis, J. P. A., Thabane, L., Gluud, L.-L., Als-Nielsen, B., & Gluud, C. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyn179 · Cited by 833
Bassler, D. (2010) · JAMA · doi:10.1001/jama.2010.310 · Cited by 611
Metadata
- Authors
- Pocock, S. J.
- Venue
- Clinical Trials
- Publisher
- SAGE Publications
- Published
- 2006-12
- Volume
- 3
- Issue
- 6
- Pages
- 513-521
- ISSN
- 1740-7745 (ISSN-L)
- 1740-7753
- OpenAlex
- W2039510404
- Cited by
- 81
- References
- 12
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current controversies in data monitoring for clinical trials. https://app.cochat.ai/papers/10.1177/1740774506073467
- The paper
- Pocock, S. J. (2006). Current controversies in data monitoring for clinical trials. Clinical Trials. https://doi.org/10.1177/1740774506073467
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.